Annals of Oncology Review Time

The official guide is more helpful than many authors realize. It says three things that matter for timing:

• papers of insufficient priority are returned within 3 weeks whenever possible
• authors are normally notified of acceptance, rejection, or revision within 6 weeks
• the journal publishes findings of particular significance in clinical oncology and clinically oriented cancer research

That means the review-time question is tightly tied to the priority question. If the study is not broad or decisive enough, the journal tries to tell you quickly. If the study is important enough to go out, you should still expect a more demanding path than the six-week headline may suggest because revisions, competing reviewer views, and translational validation can all lengthen the real cycle.

The point is not that every paper receives a polished verdict in exactly six weeks. It is that the journal tries to distinguish fast between work that belongs in the conversation and work that does not.

This journal has one of the clearest editorial filters in oncology. The guide says it publishes findings of particular significance. That is not generic prestige language. It is a sorting rule.

Editors can reject quickly when a manuscript is:

• clinically respectable but not practice-changing
• biomarker-heavy without enough independent validation
• translationally interesting but too narrow for broad oncology relevance
• mature enough for a specialty audience but not for an ESMO flagship

That is why fast rejection here does not mean bad science. It usually means the journal does not think the study clears its priority bar.

The slower Annals papers are usually the ones that survive because they are credible, but not yet obviously decisive.

Those cases often involve:

• strong efficacy data with unresolved maturity questions
• biomarker or resistance claims that need firmer validation
• disagreement about how broadly the findings change treatment decisions
• international applicability questions, especially when care pathways differ across regions
• revision cycles where the clinical story is clear but the translational layer still needs tightening

At this level, review time often tracks decision significance, not editorial congestion.

Annals of Oncology is up from 56.4 in 2023 to 65.4 in 2024, and up dramatically from 14.2 in 2017 to 65.4 in 2024. The 46.8 five-year JIF shows the citation strength is not only short-cycle trial hype. For authors, this usually means the journal has even less reason to blur its triage logic. Demand is strong enough that speed and selectivity can coexist.

The official timing language hides some real variation:

• a fast return for insufficient priority shortens the apparent cycle
• borderline papers can take longer because editors are deciding whether the clinical consequence is broad enough
• a revision request can still be expensive in time if the translational layer is underbuilt
• high-profile trial and biomarker papers often trigger heavier reviewer expectations than the headline timing suggests

So the published timing is useful, but it is not a promise that every reviewed paper will feel quick.

In our pre-submission review work, the biggest avoidable timing mistake is assuming the clinical priority case can live mainly in the cover letter. At Annals of Oncology, the title, abstract, and first results have to make that case early. If the paper only becomes important after a long explanation, the editor often decides it is not an Annals paper before reviewers ever see it.

The manuscripts that move more cleanly are usually the ones where the practice consequence is obvious on page one and the translational work is clearly in service of that consequence.

For Annals of Oncology, review time is a secondary variable. The primary variable is whether the paper is genuinely priority oncology.

That is why the better next reads are:

• Annals of Oncology journal profile
• Annals of Oncology submission guide
• Annals of Oncology impact factor
• Annals of Oncology vs. Journal of Clinical Oncology

A Annals of Oncology clinical-priority check is usually more useful than trying to optimize around one timing estimate.

Annals of Oncology review time is best understood as a priority filter. If the manuscript is not competitive for this audience, the journal often tries to say so within three weeks. If the manuscript is competitive, the first outcome can still come fairly quickly, but the harder question becomes whether the study is mature and broad enough to survive top-tier oncology scrutiny. That is the real timeline.